Cargando…

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized therapy. A smaller subset of neoantigens includes epitopes that...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinov, Tijana, Greenberg, Philip D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470615/
https://www.ncbi.nlm.nih.gov/pubmed/37655310
http://dx.doi.org/10.1146/annurev-cancerbio-061521-082114